Hylenex.com

is your portal to the first and only FDA-approved recombinant hyaluronidase. Hylenex recombinant (hyaluronidase human injection) is indicated as an adjuvant in subcutaneous fluid administration, and to increase the dispersion and absorption of other injected drugs.

For further information, contact Halozyme toll free at 855-HYLENEX (855-495-3639).

Please see Important Safety Information and accompanying package insert for Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

Hylenex recombinant (hyaluronidase human injection) is a tissue modifier indicated as an adjuvant in subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs, and in subcutaneous urography for improving resorption of radiopaque agents.

Important Safety Information

Hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product.
Discontinue Hylenex recombinant (hyaluronidase human injection) if sensitization occurs.
Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
Hyaluronidase should not be used to reduce the swelling of bites or stings.
Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
Hyaluronidase should not be applied directly to the cornea.

The most frequently reported adverse experiences have been local injection site reactions, such as erythema and pain. Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug products.

Patients receiving large doses of salicylates, cortisone, ACTH, estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase.

Edema has been reported most frequently in association with subcutaneous fluid administration.

The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. As with all parenteral fluid therapy, use the same precautions for restoring fluid and electrolyte balance. Special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of infusion. When solutions devoid of inorganic electrolytes are given subcutaneously, hypovolemia may occur.